<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265511</url>
  </required_header>
  <id_info>
    <org_study_id>SCY-635-201</org_study_id>
    <nct_id>NCT01265511</nct_id>
  </id_info>
  <brief_title>Study of SCY-635, Pegasys and Copegus in Hepatitis C</brief_title>
  <official_title>A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scynexis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scynexis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effectiveness of 28 days of triple combination therapy including
      SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An
      additional 20 weeks of treatment with the currently approved standard of care will be offered
      to all participants. The Week 24 visit will be the last on-study visit. After the Week 24
      visit, all subjects with undetectable HCV RNA will be given the option to continue treatment
      with standard of care for an additional 24 weeks (out to Week 48) under the care of their
      Principal Investigator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      The primary objective of this Phase 2a study was to assess the effect of treatment with
      SCY-635, used in combination with peginterferon alfa-2a (PegIFN α-2a) and ribavirin (RBV), on
      hepatitis C viral replication (as measured by quantitative serum HCV RNA) in treatment-naive
      subjects with chronic genotype 1 infection who have an IL28B genotype of C/T or T/T.

      The secondary objective of the study was to evaluate the safety and pharmacokinetics (PK) of
      SCY-635 when given in combination with PegIFN α-2a and RBV.

      Primary Endpoints:

      Proportion of subjects in each cohort with an undetectable serum HCV RNA level at Week 4 of
      treatment

      Secondary Endpoints:

      Adverse events and clinical laboratory assessments, including tests of liver function
      Proportion of subjects achieving complete early virologic response (cEVR, defined as an
      undetectable serum HCV RNA level at Week 12) Proportion of subjects achieving partial early
      virologic response (pEVR, defined as a detectable serum HCV RNA level with ≥ 2 log10
      reduction in serum HCV RNA from Baseline to Week 12) Proportion of subjects achieving an
      undetectable serum HCV RNA level at Week 24 Pharmacokinetic assessments of SCY-635 when given
      in combination with PegIFN α-2a and RBV; trough concentrations of PegIFN α-2a and RB
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV RNA</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Undetectable HCV RNA</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Early Virologic Response</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of subjects with detectable HCV RNA that achieve a &gt; or = 2 log reduction in HCV RNA from baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Undetectable HCV RNA</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCY-635 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets given bid for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Batch # BMR/10/731</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCY-635</intervention_name>
    <description>SCY-635 tablets, 300 mg bid for 28 days</description>
    <arm_group_label>SCY-635 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>180 ug prefilled syringe given once per week for up to 48 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>SCY-635 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copegus</intervention_name>
    <description>tablets given bid for up to 48 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>SCY-635 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Quantifiable serum levels of HCV-specific RNA in excess of 100,000 IU/mL

          -  Chronic HCV status

          -  HCV genotype 1 infection and IL28B genotype of C/T or T/T

          -  Liver biopsy results within 3 years prior to screening indicating the absence of
             cirrhosis

             *If no previous biopsy is available, a biopsy must be performed during the screening
             period to qualify for randomization

          -  Body mass index (BMI) between 18 and 38 kg/m2

          -  Laboratory variables within acceptable ranges:

               -  ALT/AST &lt; 3 × ULN;

               -  HgB &gt; 12g/dL for females, &gt; 13 g/dL for males;

               -  total WBC count &gt; 3000/mm3 and ANC &gt; 1500/mm3;

               -  platelets &gt; 100,000/mm3;

               -  prothrombin time (or INR) ≤ 1.2 × ULN;

               -  serum albumin ≥ 3.4 g/dL;

               -  total bilirubin WNL;

               -  serum creatinine WNL; if serum creatinine is &gt; ULN, then calculated creatinine
                  clearance must be &gt; 100 mL/min (by Cockcroft-Gault formula) for subject to be
                  eligible

          -  Subjects of childbearing potential (i.e., not surgically sterile or postmenopausal)
             must agree to use 2 forms of contraception from Screening until 24 weeks after
             completion of treatment with RBV

          -  Negative urine testing for amphetamines and cocaine at Screening.

          -  If female, the subject has a negative pregnancy test at Screening and on study Day 1

        Exclusion Criteria:

          -  History of clinically significant gastrointestinal, renal, hepatic, neurologic,
             hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or
             cardiovascular disease

          -  Females who are pregnant or breastfeeding

          -  Males with partners who are pregnant or are planning to become pregnant

          -  HCV genotype other than genotype 1 and an IL28B genotype of C/C

          -  Seropositive for HIV-1 or HIV-2 or hepatitis B virus (HBV) surface antigen (HBsAg)

          -  Use of any investigational agent within 3 months prior to dosing

          -  Received any prior FDA-approved or investigational drug or drug regimen for the
             treatment of hepatitis C

          -  Evidence of cirrhosis on a previous liver biopsy

          -  Evidence of decompensated liver disease

          -  Recipient of an organ transplant

          -  Evidence of hepatocellular carcinoma

          -  Evidence of ongoing alcohol or substance abuse

          -  Poorly-controlled diabetes mellitus

          -  Congestive heart failure or unstable cardiopulmonary condition, renal disease, or
             hemoglobinopathy (sickle cell anemia or thalassemia

          -  History of seizure disorder

          -  History of severe psychiatric illness, including severe depression, history of
             suicidal ideation, suicidal attempts, related hospitalizations, bipolar disorder, or
             psychosis requiring medication

          -  Concurrent medical condition or laboratory abnormality that would constitute a
             contra-indication for interferon use

          -  History of unstable thyroid disease that would preclude administration of
             interferon-based therapy

          -  Medical condition that requires use of systemic corticosteroids

          -  Received warfarin or other anticoagulants during the 21 days immediately prior to
             Screening, or is expected to require warfarin or other anticoagulants during the
             study.

          -  One or more additional known primary or secondary causes of liver disease, other than
             hepatitis C

          -  Any other concurrent medical condition likely to preclude compliance with the schedule
             of evaluations, or likely to confound the efficacy or safety observations

          -  12-lead ECG showing the following:

               -  Corrected QTc interval ≥ 450 msec (Bazett's correction);

               -  QRS &gt; 120 msec;

               -  Clinically significant abnormalities;

          -  Severe retinopathy or other significant ophthalmological disorder

          -  Use of any herbal supplements within 28 days prior to dosing.

          -  The use of CYP3A inducers or inhibitors for at least 2 weeks prior to initiation of
             treatment through Week 6
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Muir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keyur Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Ressearch Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigation de Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <results_first_submitted>October 22, 2014</results_first_submitted>
  <results_first_submitted_qc>July 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2017</results_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>SCY-635</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Placebo: Oral tablets given bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>SCY-635 600 mg</title>
          <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
SCY-635: SCY-635 tablets, 300 mg bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met stopping rules</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Placebo: Oral tablets given bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>SCY-635 600 mg</title>
          <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
SCY-635: SCY-635 tablets, 300 mg bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" spread="15.56"/>
                    <measurement group_id="B2" value="44.6" spread="8.67"/>
                    <measurement group_id="B3" value="45.1" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL28B genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IL28B_CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL28B_TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>HCV_1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV_1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA</title>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.21" spread="0.05"/>
                    <measurement group_id="B2" value="6.3" spread="0.49"/>
                    <measurement group_id="B3" value="6.48" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Undetectable HCV RNA</title>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Placebo: Oral tablets given bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCY-635 600 mg</title>
            <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
SCY-635: SCY-635 tablets, 300 mg bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Undetectable HCV RNA</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Undetectable HCV RNA</title>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Placebo: Oral tablets given bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCY-635 600 mg</title>
            <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
SCY-635: SCY-635 tablets, 300 mg bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Undetectable HCV RNA</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Early Virologic Response</title>
        <description>Proportion of subjects with detectable HCV RNA that achieve a &gt; or = 2 log reduction in HCV RNA from baseline to Week 12</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Placebo: Oral tablets given bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCY-635 600 mg</title>
            <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
SCY-635: SCY-635 tablets, 300 mg bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Early Virologic Response</title>
          <description>Proportion of subjects with detectable HCV RNA that achieve a &gt; or = 2 log reduction in HCV RNA from baseline to Week 12</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Undetectable HCV RNA</title>
        <time_frame>Week 24</time_frame>
        <population>Week 24 analysis does not include the 2 placebo subjects because they were discontinued for lack of efficacy before week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Placebo: Oral tablets given bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCY-635 600 mg</title>
            <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
SCY-635: SCY-635 tablets, 300 mg bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Undetectable HCV RNA</title>
          <population>Week 24 analysis does not include the 2 placebo subjects because they were discontinued for lack of efficacy before week 24.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Placebo: Oral tablets given bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>SCY-635 600 mg</title>
          <description>SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
SCY-635: SCY-635 tablets, 300 mg bid for 28 days
peginterferon alfa 2a: 180 ug prefilled syringe given once per week for up to 48 weeks
Ribavirin: tablets given bid for up to 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katyna Borroto-Esoda</name_or_title>
      <organization>Scynexis</organization>
      <phone>9192374431</phone>
      <email>katyna.borroto-esoda@scynexis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

